{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T06:15:09Z","timestamp":1783318509579,"version":"3.54.6"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally, with high recurrence rates limiting the success of curative treatments. Neoadjuvant therapy has recently arisen as a promising strategy to enhance surgical outcomes and survival. This review focuses specifically on neoadjuvant therapy for resectable HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main findings<\/jats:title>\n                    <jats:p>We summarize current neoadjuvant approaches in this defined setting, focusing on systemic therapies\u2014including targeted agents, immune checkpoint inhibitors, and their combinations\u2014as well as locoregional modalities such as transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), ablation, and radiotherapy. Systemic\u2013locoregional combinations have demonstrated improved pathological response rates and event-free survival, with phase 2\/3 trials such as CARES-009 providing the highest level of evidence to date. We further summarize progress in biomarkers for predicting treatment efficacy across molecular, cellular, histopathological, and imaging dimensions. Key advances include baseline immune activation signatures, dynamic serum biomarkers such as alpha-fetoprotein (AFP) kinetics and liquid biopsy indicators, and emerging radiomic signatures and spatial multi-omics approaches. We also highlight ongoing clinical trials that are evaluating novel combination regimens and biomarker-driven patient stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>By identifying critical challenges in standardizing pathological response criteria, optimizing treatment duration and sequencing, and validating multimodal biomarkers, this review emphasizes the pivotal role of neoadjuvant therapy in reshaping curative-intent management for HCC and delineates actionable directions for future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1809834","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:37:03Z","timestamp":1783316223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant therapy for hepatocellular carcinoma: emerging combinations and biomarker challenges"],"prefix":"10.3389","volume":"17","author":[{"given":"Suruiya","family":"Palihati","sequence":"first","affiliation":[{"name":"Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University","place":["Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjun","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhongshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocui","family":"Ye","sequence":"additional","affiliation":[{"name":"Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University","place":["Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Yi","sequence":"additional","affiliation":[{"name":"Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University","place":["Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.06.005","article-title":"Cancer survival statistics in China 2019-2021: a multicenter, population-based study","volume":"4","author":"Zeng","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1355812","article-title":"Neoadjuvant systemic therapy for hepatocellular carcinoma","volume":"15","author":"Chick","year":"2024","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1097\/SLA.0000000000002889","article-title":"Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma","volume":"268","author":"Pinna","year":"2018","journal-title":"Ann Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.02.013","article-title":"Neoadjuvant treatment in renal cell carcinoma: transforming challenges into opportunities","volume":"81","author":"Marandino","year":"2022","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2018.10.014","article-title":"Post-neoadjuvant strategies in breast cancer: from risk assessment to treatment escalation","volume":"72","author":"Pelizzari","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2404601","article-title":"Neoadjuvant treatment of mismatch repair-deficient colon cancer - clinically meaningful","volume":"390","author":"Cercek","year":"2024","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00276","article-title":"SAKK 16\/14: Durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial","volume":"39","author":"Rothschild","year":"2021","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1477-2574.2012.00552.x","article-title":"Risk factors of post\u2010operative recurrence and adequate surgical approach to improve long\u2010term outcomes of hepatocellular carcinoma","volume":"15","author":"Shindoh","year":"2013","journal-title":"HPB"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17474124.2024.2419519","article-title":"Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma","volume":"18","author":"Stefanini","year":"2024","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2069097","article-title":"What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy","volume":"22","author":"Bilusic","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2025.1531852","article-title":"Neoadjuvant therapy for hepatocellular carcinoma\u2014priming precision innovations to transform HCC treatment","volume":"12","author":"Goodsell","year":"2025","journal-title":"Front Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41698-025-00846-4","article-title":"Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma","volume":"9","author":"Akula","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101905","article-title":"Latin American expert opinion letter on the feasibility of systemic therapies in combination with locoregional therapies for hepatocellular carcinoma","volume":"30","author":"Anders","year":"2025","journal-title":"Ann Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001269","article-title":"Critical update: AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"82","author":"Taddei","year":"2025","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"B19","unstructured":"NCCN guidelines: Hepatobiliary cancers\n          \n          \n          NCCN\n          \n          2024"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00189","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update clinical insights","volume":"20","author":"Rose","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000541249","article-title":"Consensus of Chinese experts on neoadjuvant and conversion therapies for hepatocellular carcinoma: 2023 update","volume":"14","author":"Bi","year":"2025","journal-title":"Liver Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1200\/jco.2016.34.4_suppl.252","article-title":"BIOSHARE multicenter neoadjuvant phase 2 study: results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)\u2014from GERCOR IRC","volume":"34","author":"Bouattour","year":"2016","journal-title":"JCO"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172818","article-title":"Surgical outcomes of lenvatinib treatment followed by liver resection for advanced hepatocellular carcinoma larger than 10 cm","volume":"17","author":"Yokoo","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S357313","article-title":"Neoadjuvant therapy for hepatocellular carcinoma","volume":"9","author":"Yin","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1429919","article-title":"Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis","year":"2020","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00760-3","article-title":"Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma","volume":"20","author":"Lucas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.7333","article-title":"Neoadjuvant dual checkpoint inhibitors vs anti-PD1 therapy in high-risk resectable melanoma: a pooled analysis","volume":"10","author":"Mangla","year":"2024","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000541250","article-title":"Tissue and imaging biomarkers of response to neoadjuvant nivolumab or nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma","volume":"103","author":"LaPelusa","year":"2024","journal-title":"Oncology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1200\/JCO.2022.40.16_suppl.4093","article-title":"Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: the PRIME-HCC trial","volume":"40","author":"D\u2019Alessio","year":"2022","journal-title":"JCO"},{"key":"B37","doi-asserted-by":"publisher","first-page":"S0168827825024717","DOI":"10.1016\/j.jhep.2025.08.035","article-title":"Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration","volume":"84","author":"Lin","year":"2025","journal-title":"J Hepatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000514313","article-title":"Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations","volume":"10","author":"Zhu","year":"2021","journal-title":"Liver Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12530-z","article-title":"Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-PD-1 antibody therapy for patients with unresectable hepatocellular carcinoma","volume":"30","author":"Zhu","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01720-9","article-title":"Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial","volume":"406","author":"Wang","year":"2025","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nat Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13073-023-01218-y","article-title":"Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence","volume":"15","author":"Zhang","year":"2023","journal-title":"Genome Med"},{"key":"B44","article-title":"The negative effect of preoperative transcatheter arterial chemoembolization on long-term outcomes for resectable hepatocellular carcinoma: A propensity score matching analysis","volume":"59","author":"Amisaki","year":"2016","journal-title":"Yonago Acta Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2024.03.1159","article-title":"Prognostic benefit of preoperative transarterial chemoembolization in upfront resectable large hepatocellular carcinoma: a multicentric propensity score based analysis of European high-volume centers","volume":"26","author":"Giannone","year":"2024","journal-title":"HPB (Oxford)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1101162","article-title":"Hepatectomy versus transcatheter arterial chemoembolization for resectable BCLC stage A\/B hepatocellular carcinoma beyond Milan criteria: a randomized clinical trial","volume":"13","author":"Fang","year":"2023","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-022-03131-6","article-title":"Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients","volume":"192","author":"Zhu","year":"2023","journal-title":"Ir J Med Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107106","article-title":"Neoadjuvant drug-eluting bead transarterial chemoembolization and tislelizumab therapy for resectable or borderline resectable hepatocellular carcinoma: a propensity score matching analysis","volume":"49","author":"Zhao","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.985380","article-title":"Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: a multicenter retrospective study","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00262-025-04136-7","article-title":"Comparing neoadjuvant targeted therapy plus transarterial chemoembolization versus triple therapy including immunotherapy in hepatocellular carcinoma: a Chinese multicentre study","volume":"74","author":"Yu","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405749","article-title":"Single-nucleus and spatial transcriptome profiling delineates the multicellular ecosystem in hepatocellular carcinoma after hepatic arterial infusion chemotherapy","volume":"12","author":"Huang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002437","article-title":"Neoadjuvant hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for resectable single large hepatocellular carcinoma","volume":"111","author":"Hu","year":"2025","journal-title":"Int J Surg"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1223632","article-title":"Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus","volume":"14","author":"Hu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.4023","article-title":"Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A\/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial","volume":"41","author":"Wei","year":"2023","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003253","article-title":"Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: Analysis from the US multicenter HCC transplant consortium","volume":"271","author":"DiNorcia","year":"2020","journal-title":"Ann Surg"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i24.3872","article-title":"Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma","volume":"19","author":"Ni","year":"2013","journal-title":"World J Gastroenterol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25314","article-title":"Midterm outcomes in patients with intermediate\u2010sized hepatocellular carcinoma: A randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization","volume":"116","author":"Morimoto","year":"2010","journal-title":"Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2523081676","article-title":"Small hepatocellular carcinoma: Is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment","volume":"252","author":"Shibata","year":"2009","journal-title":"Radiology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2022.2051613","article-title":"The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion","volume":"39","author":"Peng","year":"2022","journal-title":"Int J Hyperthermia"},{"key":"B60","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/hepr.13633","article-title":"Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma","volume":"51","author":"Oyama","year":"2021","journal-title":"Hepatol Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.4702","article-title":"Phase 2 evaluation of neoadjuvant intensity-modulated radiotherapy in centrally located hepatocellular carcinoma: A nonrandomized controlled trial","volume":"157","author":"Wu","year":"2022","journal-title":"JAMA Surg"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2018.01.006","article-title":"Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: A feasibility and safety pilot study","volume":"20","author":"Lemaire","year":"2018","journal-title":"HPB (Oxford)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1038\/s41467-024-47420-3","article-title":"Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: The Notable-HCC phase 1b trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02184","article-title":"Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: A randomized, open-label, multicenter controlled study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1051916","article-title":"Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: Protocol of an open-label, single-arm, prospective, multi-center phase I trial","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0466-x","article-title":"Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: The Blueprint-HCC study","volume":"120","author":"Pinato","year":"2019","journal-title":"Br J Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","author":"Wheeler","year":"2017","journal-title":"Cell"},{"key":"B68","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2018.11.011","article-title":"p53 represses the mevalonate pathway to mediate tumor suppression","volume":"176","author":"Moon","year":"2019","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.10.038","article-title":"Update on biomarkers of hepatocellular carcinoma","volume":"13","author":"Chaiteerakij","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06532.x","article-title":"Lens culinaris agglutinin-reactive fraction of AFP is a useful prognostic biomarker for survival after repeat hepatic resection for HCC","volume":"26","author":"Matsuda","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25956","article-title":"FGF3\/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma","volume":"57","author":"Arao","year":"2013","journal-title":"Hepatology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","article-title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study","volume":"14","author":"Santoro","year":"2013","journal-title":"Lancet Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2175","article-title":"Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26151","article-title":"Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection","volume":"57","author":"Sun","year":"2013","journal-title":"Hepatology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2459","article-title":"Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma","volume":"78","author":"Qi","year":"2018","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2008.104653","article-title":"Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma","volume":"54","author":"Chan","year":"2008","journal-title":"Clin Chem"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1515\/medgen-2023-2065","article-title":"The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization","volume":"35","author":"Bronkhorst","year":"2023","journal-title":"Med Gen"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1439","article-title":"Moving forward liquid biopsy in early liver cancer detection","volume":"13","author":"Rolfo","year":"2023","journal-title":"Cancer Discov"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02119-4","article-title":"Tumour-infiltrating lymphocytes: From prognosis to treatment selection","volume":"128","author":"Brummel","year":"2023","journal-title":"Br J Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5009\/gnl.2014.8.1.79","article-title":"Prognostic significance of p53, mTOR, c-Met, IGF-1R, and HSP70 overexpression after the resection of hepatocellular carcinoma","volume":"8","author":"Kang","year":"2014","journal-title":"Gut Liver"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.162","article-title":"Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma","volume":"29","author":"Nguyen","year":"2016","journal-title":"Mod Pathol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2024.04.001","article-title":"Deep learning of pretreatment multiphase CT images for predicting response to lenvatinib and immune checkpoint inhibitors in unresectable hepatocellular carcinoma","volume":"24","author":"Liao","year":"2024","journal-title":"Comput Struct Biotechnol J"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008953","article-title":"Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy","volume":"12","author":"Hua","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.023","article-title":"Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma","volume":"70","author":"Xu","year":"2019","journal-title":"J Hepatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.04.017","article-title":"Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma","volume":"83","author":"Vithayathil","year":"2025","journal-title":"J Hepatol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41698-025-00979-6","article-title":"A multimodal fusion system predicting survival benefits of immune checkpoint inhibitors in unresectable hepatocellular carcinoma","volume":"9","author":"Xu","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.1038\/s41598-024-57078-y","article-title":"Investigation of deep learning model for predicting immune checkpoint inhibitor treatment efficacy on contrast-enhanced computed tomography images of hepatocellular carcinoma","volume":"14","author":"Nakao","year":"2024","journal-title":"Sci Rep"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-21-328","article-title":"Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-021-05181-0","article-title":"Impact of hepatectomy for advanced hepatocellular carcinoma with major portal vein tumor thrombus","volume":"26","author":"Komatsu","year":"2022","journal-title":"J Gastrointestinal Surg"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.16139\/j.1007-9610.2022.02.010","article-title":"Current status and future prospects of hepatocellular carcinoma conversion therapy","volume":"27","author":"Sun","year":"2022","journal-title":"J Surg Concepts Pract 2022"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000054","article-title":"Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial","volume":"7","author":"Guo","year":"2023","journal-title":"Hepatol Commun"},{"key":"B96","doi-asserted-by":"publisher","first-page":"55","DOI":"10.21037\/cco.2018.09.05","article-title":"Neoadjuvant therapy: Theoretical, biological and medical consideration","volume":"7","author":"Imyanitov","year":"2018","journal-title":"Chin Clin Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12943-024-02101-z","article-title":"Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma","volume":"23","author":"Chan","year":"2024","journal-title":"Mol Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"20827","DOI":"10.1038\/s41598-023-47580-0","article-title":"EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma","volume":"13","author":"Kocheise","year":"2023","journal-title":"Sci Rep"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-22-527","article-title":"Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: A narrative review","volume":"13","author":"Wang","year":"2024","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32758","article-title":"Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH","volume":"77","author":"Tan","year":"2023","journal-title":"Hepatology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4551","article-title":"Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1809834\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:37:08Z","timestamp":1783316228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1809834\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":102,"alternative-id":["10.3389\/fimmu.2026.1809834"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1809834","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1809834"}}